Literature DB >> 22762941

Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform.

Anetta Undas1, Mariola Cieśla-Dul, Tomasz Drążkiewicz, Jerzy Sadowski.   

Abstract

We tested the hypothesis that fibrin structure/function is unfavorably altered in patients with residual vein obstruction (RVO). Ex vivo plasma fibrin clot permeability, turbidimetry and efficiency of fibrinolysis were investigated in 86 patients with RVO following first-ever proximal deep vein thrombosis (DVT), and 86 DVT controls with no evidence of RVO. The RVO patients had 14.1% lower clot permeability (p=0.011), 11.3% longer lysis time (p=0.009) and 7.8% lower rate of D-dimer release from fibrin clots than controls (p=0.022), with no differences related to thrombophilia, and duration or stability of anticoagulant therapy. RVO patients showed higher lipoprotein(a) (p=0.014) with overrepresentation of smaller apolipoprotein(a) isoforms, corresponding approximately to 21 or fewer kringle IV type 2 repeats (p=0.09), both associated with alterations to plasma fibrin clot characteristics. In conclusion, prothrombotic plasma fibrin clot phenotype related to elevated lipoprotein(a) with smaller apolipoprotein(a) isoforms might represent a novel risk factor for RVO.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22762941     DOI: 10.1016/j.thromres.2012.06.005

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Authors:  Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2019-09-24       Impact factor: 5.922

Review 2.  Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.

Authors:  Alisa S Wolberg; Yaqiu Sang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-06-02       Impact factor: 10.514

Review 3.  Fibrinogen and factor XIII: newly recognized roles in venous thrombus formation and composition.

Authors:  Alisa S Wolberg
Journal:  Curr Opin Hematol       Date:  2018-09       Impact factor: 3.284

4.  Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism.

Authors:  Elena Sticchi; Alberto Magi; Pia R Kamstrup; Rossella Marcucci; Domenico Prisco; Ida Martinelli; Pier Mannuccio Mannucci; Rosanna Abbate; Betti Giusti
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

Review 5.  Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence.

Authors:  Anetta Undas
Journal:  Biomed Res Int       Date:  2017-06-27       Impact factor: 3.411

6.  Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism.

Authors:  Aneta Stachowicz; Michal Zabczyk; Joanna Natorska; Maciej Suski; Rafał Olszanecki; Ryszard Korbut; Jacek R Wiśniewski; Anetta Undas
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

7.  Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties.

Authors:  Anna Aleksandra Skuza; Maciej Polak; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2019-01       Impact factor: 2.300

8.  Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality.

Authors:  Morten Kaltoft; Kathrine Sofia Glavind; Sune Fallgaard Nielsen; Anne Langsted; Kasper Karmark Iversen; Børge Grønne Nordestgaard; Pia Rørbæk Kamstrup
Journal:  Atherosclerosis       Date:  2022-08-02       Impact factor: 6.847

9.  Erythrocyte compression index is impaired in patients with residual vein obstruction.

Authors:  Michal Zabczyk; Joanna Natorska; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.